TALGAN

UNIVADIS - TALGAN /univadis/TALGAN.md

ATC

Μορφές: CREAM
Μορφές: NASPR.SUS
Μορφές: INH.SUS.N

Δραστικές

Δελτίο Τιμών 05/2018

Ημερομηνία barcode code περιεχομενο τιμή παραγωγός χονδρική λιανική
05/2018 2802499801018 249980101 TALGAN NASPR.SUS 100MCG/DOSEσταθ.δοσ) FLX10ML(200DOSES) 6.77 7.10 9.78
05/2018 2802499802039 249980203 TALGAN CREAM 0,025% TUBX100G 04.05 4.25 5.86
05/2018 2802499803012 249980301 TALGAN INH.SUS.N 0,25MG/ML(0.50MG/2ML ανά δόση) BTx20x2ML πλαστική φιάλη μιας δόσης (20 δόσεις) 4.16 4.36 06.01
05/2018 2802499803029 249980302 TALGAN INH.SUS.N 0,25MG/ML(0.50MG/2ML ανά δόση) BTx40x2ML πλαστική φιάλη μιας δόσης (40 δόσεις) 8.32 8.73 12.03
05/2018 2802499804019 249980401 TALGAN INH.SUS.N 0,5MG/ML(1MG/2ML ανά δόση) BTx20x2ML πλαστική φιάλη μιας δόσης (20 δόσεις) 5.85 6.14 8.46
05/2018 2802499804026 249980402 TALGAN INH.SUS.N 0,5MG/ML(1MG/2ML ανά δόση) BTx40x2ML πλαστική φιάλη μιας δόσης (40 δόσεις) 11.70 12.27 16.91
  • DRUGBANK - Budesonide
  • indication:

    For the treatment of mild to moderate active Crohn's disease. Also for the treatment of asthma, non-infectious rhinitis (including hay fever and other allergies), and for treatment and prevention of nasal polyposis.

  • pharmacology:

  • mechanism:

    The exact mechanism of action of budesonide in the treatment of Crohn's disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect.

  • toxicity:

    Single oral doses of 200 and 400 mg/kg were lethal in female and male mice, respectively. The signs of acute toxicity were decreased motor activity, piloerection and generalized edema.

  • absorprion:

    Absorption is complete following oral administration.

  • halflife:

    2.0 and 3.6 hours

  • roouteelimination:

    Budesonide is excreted in urine and feces in the form of metabolites.

  • volumedistribution:

    * 3 L/kg [asthmatic children 4 to 6 years of age]

  • clearance:

    * 0.5 L/min [Athmatic children 4 to 6 years of age]